Nippon Life Global Investors Americas Inc. Sells 10,270 Shares of AbbVie Inc. $ABBV

Nippon Life Global Investors Americas Inc. cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 19.6% during the second quarter, HoldingsChannel.com reports. The fund owned 42,080 shares of the company’s stock after selling 10,270 shares during the quarter. Nippon Life Global Investors Americas Inc.’s holdings in AbbVie were worth $10,589,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Global Retirement Partners LLC bought a new position in AbbVie in the second quarter worth approximately $18,424,000. Fielder Capital Group LLC increased its holdings in AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after purchasing an additional 43 shares during the period. SCS Capital Management LLC raised its position in AbbVie by 0.9% during the 2nd quarter. SCS Capital Management LLC now owns 13,708 shares of the company’s stock valued at $3,450,000 after purchasing an additional 126 shares in the last quarter. CORDA Investment Management LLC. raised its position in AbbVie by 0.8% during the 2nd quarter. CORDA Investment Management LLC. now owns 5,318 shares of the company’s stock valued at $1,338,000 after purchasing an additional 44 shares in the last quarter. Finally, Silverlake Wealth Management LLC lifted its holdings in shares of AbbVie by 5.1% in the 2nd quarter. Silverlake Wealth Management LLC now owns 10,027 shares of the company’s stock worth $2,523,000 after buying an additional 486 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Billionaire investor Ken Griffin increased his AbbVie position by 547% in the second quarter, highlighting institutional confidence in the company’s high dividend yield and relatively defensive business profile. Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2
• Positive Sentiment: AbbVie’s immunology franchise remains a key growth anchor, while newer medicines and its oncology pipeline are helping diversify the company beyond Humira and support its longer-term outlook. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
• Positive Sentiment: Recent quarterly results exceeded analyst expectations, with revenue up 10.2% year over year and earnings modestly ahead of consensus. Management’s third-quarter earnings outlook also points to continued operating momentum.
• Neutral Sentiment: Analysts see AbbVie and Eli Lilly as offering different combinations of growth, pipeline potential and risk; the comparison reinforces that AbbVie is viewed more as a dividend and established-product investment than a high-growth pharmaceutical story. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
• Negative Sentiment: Valuation is the main near-term concern. After its strong run, AbbVie trades at an elevated earnings multiple, leaving less room for disappointment if growth slows or pipeline investments take longer to pay off. Has AbbVie Stock Become Too Expensive to Buy?
• Negative Sentiment: Second-quarter oncology sales declined 2.4%, primarily because of falling Imbruvica revenue. Growth from Venclexta and newer products only partially offset that pressure, raising concerns about the pace of AbbVie’s portfolio transition. How Did ABBV’s Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wells Fargo & Company raised their price target on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Guggenheim raised their target price on shares of AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Stock Down 1.0%

NYSE:ABBV opened at $263.08 on Thursday. The stock has a market capitalization of $464.81 billion, a price-to-earnings ratio of 74.32, a PEG ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The firm has a 50 day moving average of $251.04 and a 200 day moving average of $228.43.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie’s payout ratio is 195.48%.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.